LYRA - Lyra Therapeutics, Inc.

QQQ $ 451.63 $ -0.22 (-0.05 %)

DIA $ 399.76 $ 0.74 (0.19 %)

SPY $ 529.24 $ 0.76 (0.14 %)

TLT $ 91.40 $ -0.62 (-0.67 %)

GLD $ 223.63 $ 3.63 (1.65 %)

Previous Close

$ 0.383

Open

$ 0.36

Bid

$ 0.38 x 600

Ask

$ 0.39 x 298

Day's Range

$ 0.36 - $ 0.41

52 Week Range

$ 0.35 - $ 6.79

Volume

5,856,331

Average Volume

Market Cap

24.52M

Beta (5Y Monthly)

$ 0.72

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	04-30-2024	03-31-2024	10-Q
2	03-22-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-12-2023	03-31-2023	10-Q
6	03-29-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-09-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	08-09-2021	06-30-2021	10-Q
13	05-11-2021	03-31-2021	10-Q
14	03-09-2021	12-31-2020	10-K
15	11-10-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-28-2020	03-31-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

$new-post-hoc-analysis-of-pooled-phase-3-data-shows-that-inpefa-sotagliflozin-reduced-risk-of-heart-failure-events-in-patients-with-preserved-ejection-fraction$

New Post-Hoc Analysis Of Pooled Phase 3 Da...
05/14/2024 11:04:04

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
05/07/2024 16:31:17

Where Lyra Therapeutics Stands With Analysts
05/07/2024 15:00:16

HC Wainwright & Co. Downgrades Lyra Therap...
05/07/2024 13:48:16

HC Wainwright & Co. analyst Matthew Caufield downgrades Lyra Therapeutics (NASDAQ:LYRA) from Buy to Neutral and announce...

Jefferies Downgrades Lyra Therapeutics to ...
05/07/2024 12:04:40

Jefferies analyst Dennis Ding downgrades Lyra Therapeutics (NASDAQ:LYRA) from Buy to Hold and lowers the price target from $...

dow-surges-over-100-points-eyepoint-pharmaceuticals-shares-plunge

Dow Surges Over 100 Points; EyePoint Pharm...
05/06/2024 19:04:00

Crude Oil Gains 1%; TreeHouse Foods Shares...
05/06/2024 16:48:16

12-health-care-stocks-moving-in-mondays-intraday-session

12 Health Care Stocks Moving In Monday's I...
05/06/2024 16:31:16

BTIG Downgrades Lyra Therapeutics to Neutral
05/06/2024 15:58:49

BTIG analyst Justin Zelin downgrades Lyra Therapeutics (NASDAQ:LYRA) from Buy to Neutral.

nasdaq-jumps-100-points-tyson-foods-sales-miss-views

Nasdaq Jumps 100 Points; Tyson Foods Sales...
05/06/2024 15:14:07

Why Lyra Therapeutics Stock Is Down 93% Today
05/06/2024 13:25:04

Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 t...

Lyra Therapeutics Shares Resume Trade
05/06/2024 12:30:25

Trading Halt: Halt status updated at 8:25:...
05/06/2024 12:25:04

Lyra Therapeutics Reports Topline Results ...
05/06/2024 12:01:14

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forwardWATERTOWN, Mass., Ma...

Trading Halt: Halted at 7:50:00 a.m. ET - ...
05/06/2024 11:50:04

HC Wainwright & Co. Reiterates Buy on Lyra...
05/01/2024 10:31:10

HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Buy and maintains $12 pri...

Lyra Therapeutics Q1 EPS $(0.35) Misses $(...
04/30/2024 20:33:30

Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $...

Cantor Fitzgerald Reiterates Overweight on...
04/17/2024 13:36:02

Cantor Fitzgerald analyst Louise Chen reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Overweight.

B of A Securities Maintains Buy on Lyra Th...
03/25/2024 10:47:11

B of A Securities analyst Jason Gerberry maintains Lyra Therapeutics (NASDAQ:LYRA) with a Buy and lowers the price target fr...

HC Wainwright & Co. Reiterates Buy on Lyra...
03/22/2024 10:40:29

HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Buy and maintains $12 pri...